Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, De Bakker PI, Haas DW, McLaren PJ. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenetics and genomics. 2015 Feb;25(25). 51-9. PMID: 25461247 [PubMed] PMCID: PMC4387236 NIHMSID: NIHMS668995.

Abstract

Efavirenz and abacavir are components of recommended first-line regimens for HIV-1 infection. We used genome-wide genotyping and clinical data to explore genetic associations with virologic failure among patients randomized to efavirenz-containing or abacavir-containing regimens in AIDS Clinical Trials Group (ACTG) protocols.